Trials / Active Not Recruiting
Active Not RecruitingNCT04586426
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 228 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talquetamab | Talquetamab will be administered by subcutaneous (SC) injection. |
| DRUG | Teclistamab | Teclistamab will be administered by SC injection. |
Timeline
- Start date
- 2020-12-15
- Primary completion
- 2025-03-18
- Completion
- 2026-10-27
- First posted
- 2020-10-14
- Last updated
- 2026-01-16
Locations
40 sites across 7 countries: United States, Australia, Canada, Israel, Japan, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04586426. Inclusion in this directory is not an endorsement.